CP-157 Analysis of the expenditure on the treatment of hepatitis C virus in 2015. (14th February 2016)

• Record Type: Journal Article
• Authors: Gorostiza-Frias, ID; Selvi-Sabater, P; Alonso-Dominguez, MT; Manresa-Ramon, N; Sanchez-Martinez, I; Bejar-Riquelme, ND; Soria-Soto, M; Najera-Perez, MD; Leon-Villar, J; Rizo-Cerda, AM
• Is Part Of: European journal of hospital pharmacy. Volume 23(2016)Supplement 1
• Page Start: A69
• Page End: A70
• Publication Date: 2016-02-14
• Subjects: Pharmacy -- Periodicals; Hospital pharmacies -- Periodicals; 615.1
• DOI: 10.1136/ejhpharm-2016-000875.157
• Languages: English
• ISSNs: 2047-9956

Abstract

Abstract : Background: With the advent of new treatments for hepatitis C, we have achieved high cure rates, although this entails a significant increase in drug spending. Purpose: To describe and analyse spending on HCV treatment in 2015. Material and methods: Data were collected prospectively from January 2015 to October 2015. The data collected were: number of patients, age, gender, total expenditure (TE), average expenditure per patient (AEPP) and percentage of expenditure per drug. The sources used were the software for prescription and dispensation SAVAC and Excel database. Results: 75 patients (74.7% male) with a median age of 55 years were included. Regarding genotype, genotype 1 was the predominant one (84.4% of patients); genotypes 3 and 4 were 7.8% each. TE was 3 040 032€ and AEPP was 40 534€. The number of patients treated with each drug and the percentage of expenditure per drug were, respectively: 65 patients (73, 4% TE) with Sovaldi (monotherapy or in combination with others drugs) or with Harvoni, 28 patients (11.65% TE) with simeprevir, 10 patients (9.22% TE) with Viekirax/Exviera, 6 patients (3.95% TE) with daclatasvir, 6 patients (<1% TE) with Pegasys and 34 patients (<1% TE) with ribavirin. The expenditure per genotype was distributed as follow: 2 564 978.63€ (84% TE) in genotype 1, 234 709.37€ (7.7% TE) in genotype 3 and 240 344€ (7.9%TE) in genotype 4. The cost per patient per genotpe was: 40 713.94€/patient in genotype 1, 39 118.22€/patient in genotype 3 and 38 390.6€/patient in genotype 4. Conclusion: Solvadi and Harvoni accounted for more than 70% of total spending in this year. It is confirmed that the highest percentage of expenditure still went to genotype 1, although new treatments for HCV are indicated for most genotypes. Finally, note that even though there were more patients treated with Sovaldi than with Harvoni, the total cost attributable to each drug was similar. References and/or Acknowledgements: Moshyk A, Martel MJ, Tahami Monfared AA, et al . Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada. J. Med Econ 2015; 1–12 McEwan P, Ward T, Webster S, et al . Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b No conflict of interest.